PETHEMAPrograma para el Tratamiento de Hemopatías Malignas
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Phase II PETHEMA 40 patients with 2007 (21) Trial of Alternating newly diagnosed MM Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma Sonneveld, P.
It was wonderful to share this honour with friends from PharmaMar, Noscira and Pethema and we will certainly look forward to celebrating with all the ERT employees who work tirelessly to ensure that the company maintains a reputation amongst its clients for innovation and service excellence." Among a raft of excellent presentations, involving a number of fantastic products, this entry is a shining example of putting the patient first, reported the judges, a worthy winner!
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Patients and diagnostic criteria: From I January 1985, to 31 December 1989, 178 patients with symptomatic multiple myeloma aged 70 or more years were entered into a randomized trial of PETHEMA (Programme for the Study and Treatment of Haematological Malignancies, Spanish Society of Haematology).